CLINICAL TRIALS PROFILE FOR GADOTERATE MEGLUMINE
✉ Email this page to a colleague
All Clinical Trials for gadoterate meglumine
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00650845 ↗ | Renal Safety Evaluation After DotaremĀ®-Enhanced MRI | Completed | Guerbet | Phase 4 | 2008-01-01 | Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial. The aim of this study was to evaluate the safety profile of gadoterate meglumine (DotaremĀ®) in patients with chronic renal insufficiency by evaluating the rate of patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate meglumine. |
NCT01010932 ↗ | Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) | Completed | Guerbet | Phase 3 | 2009-10-01 | The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease. |
NCT01012674 ↗ | Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) | Completed | Guerbet | Phase 3 | 2009-10-01 | The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for gadoterate meglumine
Condition Name
Clinical Trial Locations for gadoterate meglumine
Trials by Country
Clinical Trial Progress for gadoterate meglumine
Clinical Trial Phase
Clinical Trial Sponsors for gadoterate meglumine
Sponsor Name